Innovation in medicine is at the heart of the research based pharmaceutical industry and its important role will be examined throughout the various keynote speeches, panel discussions and workshops held during the day.
With a series of guest speakers and panellists made up of decision makers and influencers from across the healthcare environment – including Sir Andrew Dillon and Professor Karol Sikora – join ABPI CEO Stephen Whitehead as they host the ABPI 2012 Annual Conference.
Stephen Whitehead, CEO, ABPI, said:
“We need to do everything we can to encourage continued innovation in medicine. With new medicines costing an average of over £1bn to develop the cost of innovating is high, but the cost of not innovating will be far, far higher. Innovation in medicine is critical to the future of our industry, to the effectiveness of the UK healthcare environment, and most importantly, it is fundamental to the health and wellbeing of future patients.
“Innovation in medicine is a high risk, high cost process, but it is the life-blood of our industry, and the only means by which we will cure or treat heart disease, certain cancers and Alzheimer’s in the future. To make sure we can continue developing more new and improved medicines, treatments and cures we need to maintain a strong innovative pharmaceutical industry, and to do this we need to see the huge risks taken by industry rewarded.”
Venue: London Lancaster, Lancaster Terrace, London W2 2TY.
To book your place at the event, please complete our online booking form at www.abpiannualevent.com or contact our events partner.
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811
Notes to Editors
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.